Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial

Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial Article

publication date

January 23, 2023

webpage

Web of Science

published in

BRITISH JOURNAL OF DERMATOLOGY Journal

start page

22

end page

31

volume

188

issue

1